HBM Healthcare Investments

Access to a Global and Diversified Healthcare Portfolio

November 2020

Data as of 31 October 2020

HBM Healthcare Investments Ltd aims for long-term capital appreciation by investing in private and public companies within the healthcare sector worldwide

About Us

Net Performance Figures (CHF)								
		Share	NAV					
MTD		-2.4%	0.8%					
YTD		21.9%	24.4%					
2019		48.0%	33.0%					
2018		21.8%	9.9%					
2017		40.5%	25.8%					
5Y Return p.a.		26.3%	19.5%					
10Y Return p.a.		22.4%	17.4%					
Distribution yield								
2020	4.1%	2018	4.9%					
2019	4.4%	2017	5.2%					

since 2008 Global and diversified healthcare portfolio of private and publicly listed companies - with 30-45 core positions

About 60 trade sales and IPOs achieved over the last decade

Founded in 2001 and listed on SIX Swiss Exchange


- Attractive dividend yield of 3-5% (p.a.)
- International and stable shareholder base with high insider ownership percentage

Facts & Figures (CHF)

Total Assets	2'178 million
Net Assets (NAV)	1'852 million
Market Capitalisation	1'834 million
Share price	263.50
NAV per share	266.20
Discount	1.0%
LTM average daily liquidity Number of issued shares Number of shareholders	12'724 shares ~ 3.0 million 6.96 million ~ 2'900
ISIN	CH0012627250
Bloomberg Ticker	HBMN SW Equity

Portfolio Breakdown





Performance over 5 Years (CHF)



Investment Philosophy

- Fundamental long
- Bottom-up selection of companies with solid long-term growth potential
- Active lead/co-lead investor in private companies with board representation
- ► HBM takes an active role and assumes entrepreneurial responsibility together with the management team
- Maximum single position limit at time of investment up to 10% of NAV

Achievements during 2020

- 10 trade sales and IPOs generated
- Over 10 new private company investments closed
- Major clinical and regulatory milestones achieved by HBM's portfolio companies
- Focus on innovative platforms and drug candidates is bearing fruit
- ► Re-initiated market and USD currency exposure hedge
- Rich pipeline of catalysts over the next 12 to 18 months

HBM Healthcare Investments

Access to a Global and Diversified Healthcare Portfolio

Main Investments

Company	Core business	Phase of Lead Product	Ticker	Market Capitalisation (CHF m)	Ownership in %	Book Value (CHF m)	in % of total Assets
	Synthetic biology (long chain diacids, carbohydrates, special enzymes, green nylon)	Market	688065 CH (ex private)	5'142	7.1	304.4 ¹⁾	14.0
	Drug for the treatment of narcolepsy (with and without cataplexy)	Market	HRMY (ex private)	2'029	8.2	165.6	7.6
•mAbs	Developing novel antibody therapeutics for oncology targets	Phase III	YMAB (ex private)	1'567	5.5	85.4	3.9
argenx	Drugs for autoimmune and cancer diseases	Phase III	ARGX	11'009	0.6	57.1	2.6
SpringWorks	Pipeline of targeted oncology programs	Phase III	SWTX (ex private)	2'593	2.2	56.5	2.6
NIELABIO	Drug for treatment of severe inflammation and autoimmune diseases	Market	VIE (ex private)	1'600	3.2	51.2	2.4
NEURELIS	Nasal spray for the treatment of epileptic seizures	Market	Private	278*	14.6	40.6	1.9
Swixx @ BioPharma	Full representation of biopharma companies in central and eastern Europe	Market	Private	134*	27.8	38.5	1.8
biohaven	Drugs for the treatment of neurological and neuropsychiatric diseases (including rare diseases)	Market	BHVN	4'243	0.9	36.9	1.7
PACIRA	Injectable medicines with (patented) controlled release of active drug	Market	PCRX (ex private)	2'090	1.6	33.2	1.5
ALX ¢ncology	Develops immuno-oncology therapies	Phase I/II	ALXO (ex private)	1'340	2.2	29.3	1.3
Turning Point	Targeted oncology	Phase II	TPTX (ex private)	3'990	0.7	27.5	1.3

* Implied company valuation, 1) Tax on capital gain and VAT not included; lock up discount for 3 year starting August 12, 2020 reflected.

Selection of Private Company Investments



Antibody drug conjugates (ADC) pipeline for difficult to treat cancers



Developing molecular glues to degrade disease-causing proteins

CONSIG

Potent and specific immune modulation molecules - two lead assets in clinical trials (atopic dermatitis, ulcerative colitis)



Antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases

KARIUS clarity at speed**

NGS-based diagnosis of infectious diseases based on blood samples



India's leading consumer health platform with over 5.5 Million downloads and 75M annual visits

Contact Details

HBM Healthcare Investments Ltd

Bundesplatz 1 6301 Zug / Switzerland Phone + 41 41 710 75 77 Fax + 41 41 710 75 78 investor.relations@hbmhealthcare.com www.hbmhealthcare.com

Disclaimer

This document is intended to be for information purposes only and should not be construed as an offer or solicitation for the purchase of this fund. HBM has expressed its own views in this document and these may change. Past performance is not a reliable indicator of future results, prices of shares and the income from them may fall as well as rise and investors may not get back the amount originally invested. An investment entails risks, which are fully described in the prospectus. Some information quoted was obtained from external sources HBM considers to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions.